GaviLyte – CTM (GAVIS Pharmaceuticals, LLC)
Welcome to the PulseAid listing for the GaviLyte – C drug offered from GAVIS Pharmaceuticals, LLC. This Osmotic Activity [MoA],Osmotic Laxative [EPC],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | GAVIS Pharmaceuticals, LLC |
| NON-PROPRIETARY NAME: | Polyethylene Glycol-3350 and Electrolytes with Flavor Pack |
| SUBSTANCE NAME: | POLYETHYLENE GLYCOL 3350; SODIUM CHLORIDE; SODIUM BICARBONATE; POTASSIUM CHLORIDE; SODIUM SULFATE ANHYDROUS |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Osmotic Activity [MoA],Osmotic Laxative [EPC],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | POWDER, FOR SOLUTION |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2009-06-01 |
| END MARKETING DATE: | 0000-00-00 |
GaviLyte – C TM HUMAN PRESCRIPTION DRUG Details:
| Item Description | GaviLyte – C TM from GAVIS Pharmaceuticals, LLC |
| LABELER NAME: | GAVIS Pharmaceuticals, LLC |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 240; 5.84; 6.72; 2.98; 22.72(g/278.26g; g/278.26g; g/278.26g; g/278.26g; g/278.26g) |
| START MARKETING DATE: | 2009-06-01 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 43386-060_22ec8294-020f-44f0-a002-d7221dfbe991 |
| PRODUCT NDC: | 43386-060 |
| APPLICATION NUMBER: | ANDA090186 |
Other POLYETHYLENE GLYCOL 3350; SODIUM CHLORIDE; SODIUM BICARBONATE; POTASSIUM CHLORIDE; SODIUM SULFATE ANHYDROUS Pharmaceutical Manufacturers / Labelers:
